Veradigm Cleared as SEC Formally Closes Investigation

Veradigm ( (MDRX) ) has issued an announcement.

On February 20, 2026, Veradigm Inc. reported that the U.S. Securities and Exchange Commission’s Division of Enforcement had formally closed its investigation into the company and, based on information available at that time, did not intend to recommend any enforcement action. The SEC also issued similar no-action letters to former chief executive Richard J. Poulton and former chief financial officer Leah S. Jones, concluding a probe that originated after Veradigm’s voluntary disclosure in January 2024 of an audit committee-led independent review of its financial reporting and internal and disclosure controls, easing regulatory uncertainty for the company and its former executives.

The investigation’s resolution followed the company’s earlier move to self-report issues related to its financial reporting and internal controls, signaling that regulators were satisfied with the information provided and any remedial efforts taken. The formal end of the probe is likely to reduce legal and compliance overhang for Veradigm, potentially improving its standing with investors and stakeholders concerned about governance and regulatory risk.

The most recent analyst rating on (MDRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Veradigm stock, see the MDRX Stock Forecast page.

More about Veradigm

Veradigm Inc. is a U.S.-based company in the healthcare technology sector, focused on financial reporting and disclosure controls as part of its corporate governance and compliance practices. The company operates under U.S. securities regulations and interacts closely with federal oversight bodies, reflecting its public-company status and responsibilities to investors.

Average Trading Volume: 276,866

Technical Sentiment Signal: Strong Sell

Current Market Cap: $490.1M

For a thorough assessment of MDRX stock, go to TipRanks’ Stock Analysis page.